Cardiotoxicity can also develop in Her2-positive breast and stomach cancer patients treated with trastuzumab and other Her2-targeted drugs since Her2 is expressed not only in tumors but also in cardiomyocytes. The gene discussed is ERBB2; the disease is gastric cancer.